Table 4. Comparison of lung cancer screening with LDCT to other preventive health interventions.
| Intervention | Original value | Year | $/QALY saved (2012 USD) | $/QALY saved (2012 USD, sensitivity analysis) | Consistent with USPSTF guidelines | Reference |
| Lung cancer screening with LDCT in high risk population | ||||||
| Annual screening over 15 years, aged 50–64 | $28,240–$47,115 | 2012 USD | $28,240–$47,115 | - | Under review | |
| Other preventive health interventions | ||||||
| Colonoscopy every 10 years, ages 50–75 | $4,870 | 2008 CAN | $8,552 | $9,625 | Yes | [44] |
| Annual fecal occult blood screening for colorectal cancer, ages 50–75 | $15,991–$18,595 | 2008 CAN | $28,080–$32,652$31,604–$36,750 | Yes | [44] | |
| Papanicolaou (Pap) test for cervical cancer, every 3 years in women aged 20–65 | $11,835 | 2000 USD | $18,662 | $28,940 | Yes | [45] |
| Biennial mammography and clinical breast exam in women, aged 50–75 years | $34,000 | 2000 USD | $53,611 | $83,139 | Yes | [46] |
| Type 2 diabetes screening, ages 25+ | $56,649 | 1995 USD | $105,650 | $192,741 | No | [47] |
| Annual HIV testing in high risk population | $100,000 | 2001 USD | $150,745 | $223,909 | Yes | [48] |
| In-center dialysis vs. no renal replacement therapy | $129,200 | 2000 USD | $203,724 | $315,928 | Yes | [49] |
| Cholesterol-lowering medication (statin) vs. Step I dieta | $130,000–$260,000 | 1997 USD | $227,878–$455,755 | $391,442–$782,883 | - | [50] |
USD, U.S. dollars; CAN, Canadian dollars.
a
Among men with LDL> = 160 mg/dL.